title: Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
abstract: This research is aimed to study the possibility of management of severe symptoms of overactive bladder (OAB) with solifenacin and trospium in patients who receive treatment with tamsulosin due to benign prostatic hyperplasia (BPH). The 338 men more than 50 years old (average age 58.4 years) diagnosed with BPH and severe symptoms of OAB were enrolled in the study. Over three episodes of urinary incontinence per day (registration according to bladder diaries), INTERNATIONAL PROSTATE SYMPTOM SCORE: over 19, OAB-V8 questionnaire score over 32, and urodynamic disorders diagnosed using cystometry and uroflowmetry were taken as a criterion of severe symptoms of OAB. Patients of the main group during 2 months received treatment with daily combination of solifenacin 5 mg and trospium 5 mg simultaneously with tamsulosin 0.4 mg. Patients of the control group were treated only with tamsulosin. First endpoint is a quantitative assessment of patients with BPH having severe symptoms of OAB. Second endpoint is a state of the patients' lower urinary tract after the treatment. In the main group, most of urodynamic indices normalized significantly. Number of episodes of incontinence reduced from middle level 3.4 (0.8) per day to 0.9 (0.7) per day. In the control group changes of urodynamic indices were not significant. Quantity of side effects did not exceed the level which is common for antimuscarinic monotherapy. Therefore, percentage of patients with severe symptoms of OAB is not less than 44% of all cases of prostatic hyperplasia accompanied by OAB symptoms. Combination of trospium and solifenacin in standard doses is an efficient and safe method of management of severe symptoms of OAB in the course of the treatment of with tamsulosin in patients more than 50 years of age.
authors.affiliation: Far Eastern Federal University, Vladivostok, Russian Federation oton2000@mail.ru.
authors.forename: Kirill Vladimirovich
authors.initials: KV
authors.lastname: Kosilov
authors.affiliation: City Polyclinic No. 3, Vladivostok, Russian Federation.
authors.forename: Sergay A
authors.initials: SA
authors.lastname: Loparev
authors.affiliation: Far Eastern State Technical Fisheries University, Vladivostok, Russian Federation.
authors.forename: Marina A
authors.initials: MA
authors.lastname: Ivanovskaya
authors.affiliation: Medical Association No. 2, Vladivostok, Russian Federation.
authors.forename: Liliya V
authors.initials: LV
authors.lastname: Kosilova
mesh_terms: D001561:Benzilates / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D009662:Nortropanes / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D000069464:Solifenacin Succinate / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D000077409:Tamsulosin; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
chemical_list: D001561:Benzilates; D018727:Muscarinic Antagonists; D009662:Nortropanes; D013449:Sulfonamides; C003330:trospium chloride; D000077409:Tamsulosin; D000069464:Solifenacin Succinate
keywords: beginning hyperplasia prostate; overactive bladder; solifenacin; tamsulosin; trospium